FDA Policy for REMS Reqmts during COVID-19

Health Care, Pharma Industry, Strategic Planning

FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.

Read the Policy now



Related Education Resources.

All Resources

2023 EKF Workshop - Getting Clinical Trial Supplies a Seat at the Table

Topics: EKF - 2023, Project Management



2023 EKF Workshop - Expanded Access

Topics: EAP, EKF - 2023



Envisioning the Future of Clinical Supply Chains in the Next 10 Years

Topic: Supply Chain

Executive Summary


Become a member

Global Clinical Supplies Group

Join GCSG for full access...

to our educational resources, conference materials and our directory of more than 480 Clinical Supply colleagues. Experience the culture of collaboration, It only takes approximately 3 minutes 22 seconds.

Please note that membership is included and FREE of charge when you sign up for an event.